Avidity Biosciences, Inc.
Avidity Biosciences, Inc. (RNA) Stock Competitors & Peer Comparison
See (RNA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RNA | $36.27 | +9.21% | 4.4B | -12.09 | -$3.00 | N/A |
| VRTX | $469.65 | -0.55% | 120.6B | -122.62 | -$3.83 | N/A |
| REGN | $563.10 | -0.27% | 59.8B | 14.32 | $39.32 | +0.31% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $328.81 | +0.25% | 42.9B | -156.58 | -$2.10 | N/A |
| ARGX | $591.99 | +0.04% | 36.2B | 36.13 | $16.39 | N/A |
| BNTX | $115.31 | +0.65% | 27.7B | -30.75 | -$3.75 | N/A |
| SMMT | $28.67 | +3.99% | 21.3B | -84.32 | -$0.34 | N/A |
| RPRX | $36.67 | +0.22% | 20.6B | 14.97 | $2.45 | +2.35% |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
Stock Comparison
RNA vs VRTX Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, VRTX has a market cap of 120.6B. Regarding current trading prices, RNA is priced at $36.27, while VRTX trades at $469.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas VRTX's P/E ratio is -122.62. In terms of profitability, RNA's ROE is -0.27%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, RNA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check VRTX's competition here
RNA vs REGN Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, REGN has a market cap of 59.8B. Regarding current trading prices, RNA is priced at $36.27, while REGN trades at $563.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas REGN's P/E ratio is 14.32. In terms of profitability, RNA's ROE is -0.27%, compared to REGN's ROE of +0.15%. Regarding short-term risk, RNA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check REGN's competition here
RNA vs SGEN Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, RNA is priced at $36.27, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RNA's ROE is -0.27%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, RNA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check SGEN's competition here
RNA vs ALNY Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, ALNY has a market cap of 42.9B. Regarding current trading prices, RNA is priced at $36.27, while ALNY trades at $328.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas ALNY's P/E ratio is -156.58. In terms of profitability, RNA's ROE is -0.27%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, RNA is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check ALNY's competition here
RNA vs ARGX Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, ARGX has a market cap of 36.2B. Regarding current trading prices, RNA is priced at $36.27, while ARGX trades at $591.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas ARGX's P/E ratio is 36.13. In terms of profitability, RNA's ROE is -0.27%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, RNA is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check ARGX's competition here
RNA vs BNTX Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, BNTX has a market cap of 27.7B. Regarding current trading prices, RNA is priced at $36.27, while BNTX trades at $115.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas BNTX's P/E ratio is -30.75. In terms of profitability, RNA's ROE is -0.27%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, RNA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check BNTX's competition here
RNA vs SMMT Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, SMMT has a market cap of 21.3B. Regarding current trading prices, RNA is priced at $36.27, while SMMT trades at $28.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas SMMT's P/E ratio is -84.32. In terms of profitability, RNA's ROE is -0.27%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, RNA is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check SMMT's competition here
RNA vs RPRX Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, RPRX has a market cap of 20.6B. Regarding current trading prices, RNA is priced at $36.27, while RPRX trades at $36.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas RPRX's P/E ratio is 14.97. In terms of profitability, RNA's ROE is -0.27%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, RNA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check RPRX's competition here
RNA vs BGNE Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, RNA is priced at $36.27, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RNA's ROE is -0.27%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, RNA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check BGNE's competition here
RNA vs DNA-WT Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, RNA is priced at $36.27, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RNA's ROE is -0.27%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, RNA is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check DNA-WT's competition here
RNA vs GMAB Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, GMAB has a market cap of 14.4B. Regarding current trading prices, RNA is priced at $36.27, while GMAB trades at $23.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas GMAB's P/E ratio is 13.76. In terms of profitability, RNA's ROE is -0.27%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, RNA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check GMAB's competition here
RNA vs UTHR Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, UTHR has a market cap of 13.7B. Regarding current trading prices, RNA is priced at $36.27, while UTHR trades at $304.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas UTHR's P/E ratio is 12.14. In terms of profitability, RNA's ROE is -0.27%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, RNA is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check UTHR's competition here
RNA vs INCY Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, INCY has a market cap of 13.6B. Regarding current trading prices, RNA is priced at $36.27, while INCY trades at $70.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas INCY's P/E ratio is 351.03. In terms of profitability, RNA's ROE is -0.27%, compared to INCY's ROE of +0.01%. Regarding short-term risk, RNA is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check INCY's competition here
RNA vs MRNA Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, MRNA has a market cap of 13.2B. Regarding current trading prices, RNA is priced at $36.27, while MRNA trades at $34.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas MRNA's P/E ratio is -3.91. In terms of profitability, RNA's ROE is -0.27%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, RNA is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check MRNA's competition here
RNA vs KRTX Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, RNA is priced at $36.27, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RNA's ROE is -0.27%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, RNA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check KRTX's competition here
RNA vs EXEL Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, EXEL has a market cap of 12.4B. Regarding current trading prices, RNA is priced at $36.27, while EXEL trades at $45.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas EXEL's P/E ratio is 20.82. In terms of profitability, RNA's ROE is -0.27%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, RNA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check EXEL's competition here
RNA vs BMRN Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, BMRN has a market cap of 11.3B. Regarding current trading prices, RNA is priced at $36.27, while BMRN trades at $59.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas BMRN's P/E ratio is 21.86. In terms of profitability, RNA's ROE is -0.27%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, RNA is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check BMRN's competition here
RNA vs ASND Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, ASND has a market cap of 10.1B. Regarding current trading prices, RNA is priced at $36.27, while ASND trades at $167.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas ASND's P/E ratio is -24.56. In terms of profitability, RNA's ROE is -0.27%, compared to ASND's ROE of +1.91%. Regarding short-term risk, RNA is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check ASND's competition here
RNA vs RXDX Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, RNA is priced at $36.27, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas RXDX's P/E ratio is -56.47. In terms of profitability, RNA's ROE is -0.27%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, RNA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check RXDX's competition here
RNA vs TECH Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, TECH has a market cap of 9.2B. Regarding current trading prices, RNA is priced at $36.27, while TECH trades at $58.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas TECH's P/E ratio is 70.82. In terms of profitability, RNA's ROE is -0.27%, compared to TECH's ROE of +0.06%. Regarding short-term risk, RNA is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check TECH's competition here
RNA vs VRNA Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, VRNA has a market cap of 8.9B. Regarding current trading prices, RNA is priced at $36.27, while VRNA trades at $105.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas VRNA's P/E ratio is -52.65. In terms of profitability, RNA's ROE is -0.27%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, RNA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check VRNA's competition here
RNA vs BBIO Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, BBIO has a market cap of 8.8B. Regarding current trading prices, RNA is priced at $36.27, while BBIO trades at $46.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas BBIO's P/E ratio is -13.01. In terms of profitability, RNA's ROE is -0.27%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, RNA is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check BBIO's competition here
RNA vs IMGN Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, RNA is priced at $36.27, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RNA's ROE is -0.27%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, RNA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check IMGN's competition here
RNA vs BPMC Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, RNA is priced at $36.27, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas BPMC's P/E ratio is -51.58. In terms of profitability, RNA's ROE is -0.27%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, RNA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check BPMC's competition here
RNA vs CERE Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, RNA is priced at $36.27, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas CERE's P/E ratio is -16.47. In terms of profitability, RNA's ROE is -0.27%, compared to CERE's ROE of -0.43%. Regarding short-term risk, RNA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check CERE's competition here
RNA vs ROIV Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, ROIV has a market cap of 7.9B. Regarding current trading prices, RNA is priced at $36.27, while ROIV trades at $11.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas ROIV's P/E ratio is -15.40. In terms of profitability, RNA's ROE is -0.27%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, RNA is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check ROIV's competition here
RNA vs ROIVW Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, RNA is priced at $36.27, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, RNA's ROE is -0.27%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, RNA is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check ROIVW's competition here
RNA vs CORT Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, CORT has a market cap of 7.2B. Regarding current trading prices, RNA is priced at $36.27, while CORT trades at $68.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas CORT's P/E ratio is 59.38. In terms of profitability, RNA's ROE is -0.27%, compared to CORT's ROE of +0.20%. Regarding short-term risk, RNA is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check CORT's competition here
RNA vs HALO Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, HALO has a market cap of 7.2B. Regarding current trading prices, RNA is priced at $36.27, while HALO trades at $58.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas HALO's P/E ratio is 15.49. In terms of profitability, RNA's ROE is -0.27%, compared to HALO's ROE of +1.22%. Regarding short-term risk, RNA is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check HALO's competition here
RNA vs JAZZ Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, JAZZ has a market cap of 7.2B. Regarding current trading prices, RNA is priced at $36.27, while JAZZ trades at $118.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas JAZZ's P/E ratio is 16.06. In terms of profitability, RNA's ROE is -0.27%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, RNA is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check JAZZ's competition here
RNA vs RVMD Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, RVMD has a market cap of 7.1B. Regarding current trading prices, RNA is priced at $36.27, while RVMD trades at $37.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas RVMD's P/E ratio is -9.45. In terms of profitability, RNA's ROE is -0.27%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, RNA is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check RVMD's competition here
RNA vs IONS Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, IONS has a market cap of 6.7B. Regarding current trading prices, RNA is priced at $36.27, while IONS trades at $42.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas IONS's P/E ratio is -14.13. In terms of profitability, RNA's ROE is -0.27%, compared to IONS's ROE of -0.92%. Regarding short-term risk, RNA is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check IONS's competition here
RNA vs MDGL Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, MDGL has a market cap of 6.6B. Regarding current trading prices, RNA is priced at $36.27, while MDGL trades at $298.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas MDGL's P/E ratio is -16.74. In terms of profitability, RNA's ROE is -0.27%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, RNA is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check MDGL's competition here
RNA vs RETA Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, RNA is priced at $36.27, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas RETA's P/E ratio is -66.29. In terms of profitability, RNA's ROE is -0.27%, compared to RETA's ROE of +0.47%. Regarding short-term risk, RNA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check RETA's competition here
RNA vs AMRN Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, AMRN has a market cap of 6.4B. Regarding current trading prices, RNA is priced at $36.27, while AMRN trades at $15.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas AMRN's P/E ratio is -3.50. In terms of profitability, RNA's ROE is -0.27%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, RNA is more volatile compared to AMRN. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check AMRN's competition here
RNA vs TGTX Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, TGTX has a market cap of 5.9B. Regarding current trading prices, RNA is priced at $36.27, while TGTX trades at $36.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas TGTX's P/E ratio is 147.60. In terms of profitability, RNA's ROE is -0.27%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, RNA is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check TGTX's competition here
RNA vs NUVL Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, NUVL has a market cap of 5.8B. Regarding current trading prices, RNA is priced at $36.27, while NUVL trades at $81.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas NUVL's P/E ratio is -18.44. In terms of profitability, RNA's ROE is -0.27%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, RNA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check NUVL's competition here
RNA vs RYTM Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, RYTM has a market cap of 5.7B. Regarding current trading prices, RNA is priced at $36.27, while RYTM trades at $86.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas RYTM's P/E ratio is -30.88. In terms of profitability, RNA's ROE is -0.27%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, RNA is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check RYTM's competition here
RNA vs CRSP Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, CRSP has a market cap of 5.6B. Regarding current trading prices, RNA is priced at $36.27, while CRSP trades at $64.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas CRSP's P/E ratio is -14.42. In terms of profitability, RNA's ROE is -0.27%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, RNA is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check CRSP's competition here
RNA vs ABCM Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, RNA is priced at $36.27, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RNA's ROE is -0.27%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RNA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check ABCM's competition here
RNA vs ISEE Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, RNA is priced at $36.27, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RNA's ROE is -0.27%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RNA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check ISEE's competition here
RNA vs MRUS Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, MRUS has a market cap of 5B. Regarding current trading prices, RNA is priced at $36.27, while MRUS trades at $66.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas MRUS's P/E ratio is -16.06. In terms of profitability, RNA's ROE is -0.27%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, RNA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check MRUS's competition here
RNA vs AXSM Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, AXSM has a market cap of 5B. Regarding current trading prices, RNA is priced at $36.27, while AXSM trades at $100.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas AXSM's P/E ratio is -17.47. In terms of profitability, RNA's ROE is -0.27%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, RNA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check AXSM's competition here
RNA vs TLX Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, TLX has a market cap of 4.8B. Regarding current trading prices, RNA is priced at $36.27, while TLX trades at $14.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas TLX's P/E ratio is 157.78. In terms of profitability, RNA's ROE is -0.27%, compared to TLX's ROE of +0.14%. Regarding short-term risk, RNA is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check TLX's competition here
RNA vs PCVX Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, PCVX has a market cap of 4.7B. Regarding current trading prices, RNA is priced at $36.27, while PCVX trades at $36.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas PCVX's P/E ratio is -9.18. In terms of profitability, RNA's ROE is -0.27%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, RNA is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check PCVX's competition here
RNA vs SLNO Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, SLNO has a market cap of 4.6B. Regarding current trading prices, RNA is priced at $36.27, while SLNO trades at $86.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas SLNO's P/E ratio is -18.24. In terms of profitability, RNA's ROE is -0.27%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, RNA is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check SLNO's competition here
RNA vs ALPN Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, RNA is priced at $36.27, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RNA's ROE is -0.27%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, RNA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check ALPN's competition here
RNA vs CYTK Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, CYTK has a market cap of 4.4B. Regarding current trading prices, RNA is priced at $36.27, while CYTK trades at $37.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas CYTK's P/E ratio is -7.03. In terms of profitability, RNA's ROE is -0.27%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, RNA is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check CYTK's competition here
RNA vs ALKS Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, ALKS has a market cap of 4.3B. Regarding current trading prices, RNA is priced at $36.27, while ALKS trades at $26.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas ALKS's P/E ratio is 12.44. In terms of profitability, RNA's ROE is -0.27%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, RNA is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check ALKS's competition here
RNA vs ADMA Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, ADMA has a market cap of 4.3B. Regarding current trading prices, RNA is priced at $36.27, while ADMA trades at $18.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas ADMA's P/E ratio is 21.44. In terms of profitability, RNA's ROE is -0.27%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, RNA is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check ADMA's competition here
RNA vs MTSR Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, MTSR has a market cap of 4.3B. Regarding current trading prices, RNA is priced at $36.27, while MTSR trades at $40.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas MTSR's P/E ratio is -16.06. In terms of profitability, RNA's ROE is -0.27%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, RNA is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check MTSR's competition here
RNA vs KRYS Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, KRYS has a market cap of 4.3B. Regarding current trading prices, RNA is priced at $36.27, while KRYS trades at $147.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas KRYS's P/E ratio is 35.40. In terms of profitability, RNA's ROE is -0.27%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, RNA is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check KRYS's competition here
RNA vs ABVX Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, ABVX has a market cap of 4.2B. Regarding current trading prices, RNA is priced at $36.27, while ABVX trades at $66.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas ABVX's P/E ratio is -19.27. In terms of profitability, RNA's ROE is -0.27%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, RNA is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check ABVX's competition here
RNA vs OPT Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, RNA is priced at $36.27, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas OPT's P/E ratio is -1.52. In terms of profitability, RNA's ROE is -0.27%, compared to OPT's ROE of +2.60%. Regarding short-term risk, RNA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check OPT's competition here
RNA vs MRTX Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, RNA is priced at $36.27, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RNA's ROE is -0.27%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, RNA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check MRTX's competition here
RNA vs ZLAB Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, ZLAB has a market cap of 4.1B. Regarding current trading prices, RNA is priced at $36.27, while ZLAB trades at $37.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas ZLAB's P/E ratio is -14.87. In terms of profitability, RNA's ROE is -0.27%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, RNA is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check ZLAB's competition here
RNA vs AKRO Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, AKRO has a market cap of 4B. Regarding current trading prices, RNA is priced at $36.27, while AKRO trades at $50.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas AKRO's P/E ratio is -13.48. In terms of profitability, RNA's ROE is -0.27%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, RNA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check AKRO's competition here
RNA vs LEGN Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, LEGN has a market cap of 4B. Regarding current trading prices, RNA is priced at $36.27, while LEGN trades at $43.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas LEGN's P/E ratio is -36.76. In terms of profitability, RNA's ROE is -0.27%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, RNA is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check LEGN's competition here
RNA vs ACLX Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, ACLX has a market cap of 3.9B. Regarding current trading prices, RNA is priced at $36.27, while ACLX trades at $71.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas ACLX's P/E ratio is -23.85. In terms of profitability, RNA's ROE is -0.27%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, RNA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check ACLX's competition here
RNA vs ACAD Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, ACAD has a market cap of 3.9B. Regarding current trading prices, RNA is priced at $36.27, while ACAD trades at $23.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas ACAD's P/E ratio is 16.97. In terms of profitability, RNA's ROE is -0.27%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, RNA is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check ACAD's competition here
RNA vs VKTX Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, VKTX has a market cap of 3.9B. Regarding current trading prices, RNA is priced at $36.27, while VKTX trades at $34.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas VKTX's P/E ratio is -22.35. In terms of profitability, RNA's ROE is -0.27%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, RNA is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check VKTX's competition here
RNA vs RYZB Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, RNA is priced at $36.27, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas RYZB's P/E ratio is -57.86. In terms of profitability, RNA's ROE is -0.27%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, RNA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check RYZB's competition here
RNA vs CBAY Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, RNA is priced at $36.27, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas CBAY's P/E ratio is -32.81. In terms of profitability, RNA's ROE is -0.27%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, RNA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check CBAY's competition here
RNA vs SRRK Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, SRRK has a market cap of 3.7B. Regarding current trading prices, RNA is priced at $36.27, while SRRK trades at $38.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas SRRK's P/E ratio is -15.27. In terms of profitability, RNA's ROE is -0.27%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, RNA is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check SRRK's competition here
RNA vs PTCT Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, PTCT has a market cap of 3.5B. Regarding current trading prices, RNA is priced at $36.27, while PTCT trades at $44.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas PTCT's P/E ratio is 6.86. In terms of profitability, RNA's ROE is -0.27%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, RNA is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check PTCT's competition here
RNA vs SWTX Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, RNA is priced at $36.27, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas SWTX's P/E ratio is -13.78. In terms of profitability, RNA's ROE is -0.27%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, RNA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check SWTX's competition here
RNA vs MLTX Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, MLTX has a market cap of 3.5B. Regarding current trading prices, RNA is priced at $36.27, while MLTX trades at $55.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas MLTX's P/E ratio is -23.91. In terms of profitability, RNA's ROE is -0.27%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, RNA is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check MLTX's competition here
RNA vs PTGX Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, PTGX has a market cap of 3.4B. Regarding current trading prices, RNA is priced at $36.27, while PTGX trades at $55.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas PTGX's P/E ratio is 70.72. In terms of profitability, RNA's ROE is -0.27%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, RNA is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check PTGX's competition here
RNA vs KYMR Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, KYMR has a market cap of 3.2B. Regarding current trading prices, RNA is priced at $36.27, while KYMR trades at $45.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas KYMR's P/E ratio is -14.71. In terms of profitability, RNA's ROE is -0.27%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, RNA is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check KYMR's competition here
RNA vs AAPG Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, AAPG has a market cap of 3.1B. Regarding current trading prices, RNA is priced at $36.27, while AAPG trades at $37.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas AAPG's P/E ratio is -50.40. In terms of profitability, RNA's ROE is -0.27%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, RNA is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check AAPG's competition here
RNA vs CRNX Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, CRNX has a market cap of 2.9B. Regarding current trading prices, RNA is priced at $36.27, while CRNX trades at $30.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas CRNX's P/E ratio is -8.16. In terms of profitability, RNA's ROE is -0.27%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, RNA is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check CRNX's competition here
RNA vs IMVT Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, IMVT has a market cap of 2.9B. Regarding current trading prices, RNA is priced at $36.27, while IMVT trades at $16.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas IMVT's P/E ratio is -6.21. In terms of profitability, RNA's ROE is -0.27%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, RNA is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check IMVT's competition here
RNA vs MORF Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, RNA is priced at $36.27, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas MORF's P/E ratio is -14.88. In terms of profitability, RNA's ROE is -0.27%, compared to MORF's ROE of -0.22%. Regarding short-term risk, RNA is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check MORF's competition here
RNA vs MOR Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, RNA is priced at $36.27, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas MOR's P/E ratio is -12.64. In terms of profitability, RNA's ROE is -0.27%, compared to MOR's ROE of -1.84%. Regarding short-term risk, RNA is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check MOR's competition here
RNA vs RXRX Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, RXRX has a market cap of 2.8B. Regarding current trading prices, RNA is priced at $36.27, while RXRX trades at $6.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas RXRX's P/E ratio is -3.61. In terms of profitability, RNA's ROE is -0.27%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, RNA is more volatile compared to RXRX. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check RXRX's competition here
RNA vs KDNY Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, RNA is priced at $36.27, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas KDNY's P/E ratio is -12.47. In terms of profitability, RNA's ROE is -0.27%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, RNA is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check KDNY's competition here
RNA vs NAMS Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, NAMS has a market cap of 2.6B. Regarding current trading prices, RNA is priced at $36.27, while NAMS trades at $23.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas NAMS's P/E ratio is -12.83. In terms of profitability, RNA's ROE is -0.27%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, RNA is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check NAMS's competition here
RNA vs MYOV Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, RNA is priced at $36.27, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas MYOV's P/E ratio is -14.05. In terms of profitability, RNA's ROE is -0.27%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, RNA is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check MYOV's competition here
RNA vs LGND Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, LGND has a market cap of 2.6B. Regarding current trading prices, RNA is priced at $36.27, while LGND trades at $135.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas LGND's P/E ratio is -18.63. In terms of profitability, RNA's ROE is -0.27%, compared to LGND's ROE of -0.16%. Regarding short-term risk, RNA is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check LGND's competition here
RNA vs NAMSW Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, NAMSW has a market cap of 2.6B. Regarding current trading prices, RNA is priced at $36.27, while NAMSW trades at $12.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas NAMSW's P/E ratio is N/A. In terms of profitability, RNA's ROE is -0.27%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, RNA is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check NAMSW's competition here
RNA vs RARE Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, RARE has a market cap of 2.6B. Regarding current trading prices, RNA is priced at $36.27, while RARE trades at $27.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas RARE's P/E ratio is -4.69. In terms of profitability, RNA's ROE is -0.27%, compared to RARE's ROE of -1.86%. Regarding short-term risk, RNA is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check RARE's competition here
RNA vs MIRM Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, MIRM has a market cap of 2.6B. Regarding current trading prices, RNA is priced at $36.27, while MIRM trades at $51.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas MIRM's P/E ratio is -32.19. In terms of profitability, RNA's ROE is -0.27%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, RNA is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check MIRM's competition here
RNA vs CPRX Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, CPRX has a market cap of 2.6B. Regarding current trading prices, RNA is priced at $36.27, while CPRX trades at $20.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas CPRX's P/E ratio is 13.36. In terms of profitability, RNA's ROE is -0.27%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, RNA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check CPRX's competition here
RNA vs IBRX Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, IBRX has a market cap of 2.5B. Regarding current trading prices, RNA is priced at $36.27, while IBRX trades at $2.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas IBRX's P/E ratio is -5.02. In terms of profitability, RNA's ROE is -0.27%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, RNA is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check IBRX's competition here
RNA vs APLS Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, APLS has a market cap of 2.5B. Regarding current trading prices, RNA is priced at $36.27, while APLS trades at $19.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas APLS's P/E ratio is -10.88. In terms of profitability, RNA's ROE is -0.27%, compared to APLS's ROE of -1.00%. Regarding short-term risk, RNA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check APLS's competition here
RNA vs APGE Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, APGE has a market cap of 2.4B. Regarding current trading prices, RNA is priced at $36.27, while APGE trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas APGE's P/E ratio is -11.31. In terms of profitability, RNA's ROE is -0.27%, compared to APGE's ROE of -0.19%. Regarding short-term risk, RNA is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check APGE's competition here
RNA vs PRVB Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, RNA is priced at $36.27, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas PRVB's P/E ratio is -16.43. In terms of profitability, RNA's ROE is -0.27%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, RNA is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check PRVB's competition here
RNA vs LBPH Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, RNA is priced at $36.27, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas LBPH's P/E ratio is -26.66. In terms of profitability, RNA's ROE is -0.27%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, RNA is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check LBPH's competition here
RNA vs XENE Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, XENE has a market cap of 2.3B. Regarding current trading prices, RNA is priced at $36.27, while XENE trades at $30.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas XENE's P/E ratio is -9.41. In terms of profitability, RNA's ROE is -0.27%, compared to XENE's ROE of -0.32%. Regarding short-term risk, RNA is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check XENE's competition here
RNA vs AGIO Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, AGIO has a market cap of 2.3B. Regarding current trading prices, RNA is priced at $36.27, while AGIO trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas AGIO's P/E ratio is 3.47. In terms of profitability, RNA's ROE is -0.27%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, RNA is more volatile compared to AGIO. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check AGIO's competition here
RNA vs DICE Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, RNA is priced at $36.27, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas DICE's P/E ratio is -21.91. In terms of profitability, RNA's ROE is -0.27%, compared to DICE's ROE of +0.56%. Regarding short-term risk, RNA is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check DICE's competition here
RNA vs BEAM Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, BEAM has a market cap of 2.2B. Regarding current trading prices, RNA is priced at $36.27, while BEAM trades at $21.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas BEAM's P/E ratio is -4.71. In terms of profitability, RNA's ROE is -0.27%, compared to BEAM's ROE of -0.44%. Regarding short-term risk, RNA is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check BEAM's competition here
RNA vs ARWR Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, ARWR has a market cap of 2.2B. Regarding current trading prices, RNA is priced at $36.27, while ARWR trades at $15.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas ARWR's P/E ratio is -12.69. In terms of profitability, RNA's ROE is -0.27%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, RNA is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check ARWR's competition here
RNA vs HRMY Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, HRMY has a market cap of 2.2B. Regarding current trading prices, RNA is priced at $36.27, while HRMY trades at $37.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas HRMY's P/E ratio is 14.32. In terms of profitability, RNA's ROE is -0.27%, compared to HRMY's ROE of +0.24%. Regarding short-term risk, RNA is more volatile compared to HRMY. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check HRMY's competition here
RNA vs GLPG Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, GLPG has a market cap of 2.2B. Regarding current trading prices, RNA is priced at $36.27, while GLPG trades at $32.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas GLPG's P/E ratio is -6.35. In terms of profitability, RNA's ROE is -0.27%, compared to GLPG's ROE of -0.06%. Regarding short-term risk, RNA is more volatile compared to GLPG. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check GLPG's competition here
RNA vs CALT Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, RNA is priced at $36.27, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas CALT's P/E ratio is -22.73. In terms of profitability, RNA's ROE is -0.27%, compared to CALT's ROE of -1.67%. Regarding short-term risk, RNA is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check CALT's competition here
RNA vs IDYA Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, IDYA has a market cap of 2.1B. Regarding current trading prices, RNA is priced at $36.27, while IDYA trades at $24.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas IDYA's P/E ratio is -6.71. In terms of profitability, RNA's ROE is -0.27%, compared to IDYA's ROE of -0.29%. Regarding short-term risk, RNA is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check IDYA's competition here
RNA vs IMRA Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, IMRA has a market cap of 2.1B. Regarding current trading prices, RNA is priced at $36.27, while IMRA trades at $42.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas IMRA's P/E ratio is N/A. In terms of profitability, RNA's ROE is -0.27%, compared to IMRA's ROE of -0.41%. Regarding short-term risk, RNA is more volatile compared to IMRA. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check IMRA's competition here
RNA vs IRON Comparison July 2025
RNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNA stands at 4.4B. In comparison, IRON has a market cap of 2.1B. Regarding current trading prices, RNA is priced at $36.27, while IRON trades at $60.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNA currently has a P/E ratio of -12.09, whereas IRON's P/E ratio is -15.58. In terms of profitability, RNA's ROE is -0.27%, compared to IRON's ROE of -0.23%. Regarding short-term risk, RNA is more volatile compared to IRON. This indicates potentially higher risk in terms of short-term price fluctuations for RNA.Check IRON's competition here